Q32 Bio Inc. — fact timeline

Albert Seymour resigned as Director at Q32 Bio Inc..

“Dr. Seymour resigned from the Company’s board of directors, effective as of November 17, 2023.”

Albert Seymour was terminated as President and Chief Executive Officer at Q32 Bio Inc..

“the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.”

Q32 Bio Inc. announced a restructuring with charges of approximately $6.8 million (approximately 80 employees).

“On July 25, 2023, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) approved a reduction in the Company’s current workforce by approximately 80 employees. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options. The reduction in force included Julie Jordan, M.D., the Company’s Chief Medical Officer and Michael Blum, the Company’s Chief Commercial Officer. The Company intends to retain Mr. Blum as a consultant. The Company currently estimates that it will incur approximately $6.8 million in charges in connection with the reduction in force, primarily consisting of severance payments, employee benefits and related costs, including tax costs and excluding noncash expenses associated with share-based awards.”

Q32 Bio Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.

“Item 2 - Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 44,765,597 108,239 691,660 0”

Q32 Bio Inc. shareholders approved Election of two Class II Directors to serve until the Company's 2026 Annual Meeting of Stockholders at the 2023-06-14 meeting.

“NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Steven Gillis, Ph.D. 32,246,621 2,619,932 10,698,943 Albert Seymour, Ph.D. 34,681,867 184,686 10,698,943”

Jeffrey V. Poulton was appointed as Lead Director at Q32 Bio Inc..

“and has also appointed Jeffrey V. Poulton to serve as the Lead Director of the Board.”

Kush M. Parmar resigned as Chairman of the Board at Q32 Bio Inc..

“Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.”

Arthur O. Tzianabos was appointed as Chairman of the Board at Q32 Bio Inc..

“The Board has appointed Arthur O. Tzianabos, Ph.D. to replace Dr. Parmar as the Chairman of the Board”

Arthur O. Tzianabos resigned as Chief Executive Officer at Q32 Bio Inc..

“On September 6, 2022, in connection with Dr. Seymour’s promotion, Dr. Tzianabos notified the Company of his resignation as Chief Executive Officer.”

Albert Seymour was appointed as Class II Director at Q32 Bio Inc..

“Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.”

Albert Seymour was appointed as Chief Executive Officer at Q32 Bio Inc..

“On September 6, 2022, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) appointed Albert Seymour, Ph.D., the Company’s former Chief Scientific Officer and President, to serve as the Company’s Chief Executive Officer, in addition to his role as the Company’s President.”

Arthur O. Tzianabos resigned as President at Q32 Bio Inc..

“Arthur O. Tzianabos, Ph.D., in connection with Dr. Seymour’s promotion, notified the Company on April 19, 2022 of his resignation as President, effective as of April 21, 2022.”

Albert Seymour was appointed as President at Q32 Bio Inc..

“On April 19, 2022, the Board of Directors of Homology Medicines, Inc. (the “Company”) appointed Albert Seymour, Ph.D., the Company’s current Chief Scientific Officer, to serve as the Company’s President, effective as of April 21, 2022, in addition to his role as the Company’s Chief Scientific Officer.”

Tim Kelly departed as Chief Operating Officer at Q32 Bio Inc..

“Effective as of the Closing, Tim Kelly will assume the role of Chief Executive Officer and Chairman of the Board of Newco and will no longer serve as the Chief Operating Officer of Homology.”